Protagonist Therapeutics, Inc.
PTGX
Rang in Aktien
#2247
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Aktienkurs
$138.50
Marktkapitalisierung
$8.96B
Veränderung (1 Tag)
3.02%
Veränderung (1 Jahr)
80.53%
Land
US
Handel Protagonist Therapeutics, Inc. (PTGX)
Kategorie
Healthcare
P/S-Verhältnis für Protagonist Therapeutics, Inc. (PTGX)
P/S-Verhältnis zum October 2026 TTM: 31.27
Laut den neuesten Finanzberichten und dem Aktienkurs von Protagonist Therapeutics, Inc. beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 31.27. Am Ende des Jahres 2023 lag das P/S-Verhältnis bei 21.69.
P/S-Verlauf für Protagonist Therapeutics, Inc. von 2014 bis 2026
P/S-Verhältnis zum Jahresende
| Jahr | P/S-Verhältnis | ändert |
|---|---|---|
| 2026 (TTM) | 31.27 | 471.70% |
| 2024 | 5.47 | -74.78% |
| 2023 | 21.69 | 7.77% |
| 2022 | 20.13 | -65.24% |
| 2021 | 57.91 | 139.08% |
| 2020 | 24.22 | -96.93% |
| 2019 | 790.27 | 16,137.36% |
| 2018 | 4.87 | -73.47% |
| 2017 | 18.34 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/S-Verhältnis | P/S-Verhältnis-Differenz | Land |
|---|---|---|---|
| 10.02 | -67.95% |
US
|
|
| 40.55 | 29.67% |
US
|
|
| 3.96 | -87.33% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -67.55% |
NL
|
